Abstract: The present disclosure relates to combinations of a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to combinations of valproic acid or a pharmaceutically acceptable salt thereof, a ?-lactam compound or a pharmaceutically acceptable salt thereof, and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the combinations.

Abstract: An implantable fluid operated device includes a fluid control system to transfer fluid between a fluid reservoir and an inflatable member. The fluid control system includes at least one fluid control device including at least one pump and at least one valve, or at least one combination pump and valve device. A seal is provided in the at least one fluid control device. In a first mode, the seal provides a seal between a fluid passageway and a fluid chamber of the fluid control device, to close the fluid control device. In a second mode, the seal is disengaged to open the fluid control device and allow fluid to flow between the fluid passageway and the fluid chamber. A seal retention device maintains a position of the seal when the fluid control device is open and fluid is flowing through the fluid control device.

Abstract: The present disclosure relates to combinations of valproic acid or a pharmaceutically acceptable salt thereof, a ?-lactam compound or a pharmaceutically acceptable salt thereof, and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the combinations.

Abstract: The present disclosure relates to combinations of a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

Abstract: An implantable medical device can include a housing including electronic devices within the housing, and a header attached to the housing. The header can include a first silicone portion configured to surround a first portion of internal electronics of the header, and a second silicone portion configured to surround a second portion of internal electronics of the header. The header can further include a splitline where the first silicone portion abuts the second silicone portion, wherein an outer edge of the first silicone portion and an outer edge of the second silicone portion are rounded at the splitline to prevent a sharp edge that may cause damage during assembly or insertion.

Abstract: An implantable medical device can include a housing including electronic devices within the housing, a header attached to the housing and including one or more bores, an antenna extending from the housing into the header, and an antenna clip configured to position and retain the antenna relative to the header.

Abstract: An implantable medical device can include a housing including electronic devices within the housing; a header attached to the housing and including one or more bores; a wire extending from the housing into the header and coupled to an electrical contact within the bore; and a wire clip configured to position and retain the wire relative to the header.

Abstract: The present disclosure relates to combinations of a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to bilayer tablets comprising a second layer comprising a ?-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.

Abstract: The present disclosure relates to combinations of a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are systems and methods for ropeless fishing. The ropeless fishing system includes a surface subsystem installed on a vessel and at least one submerged subsystem submerged in a body of water. The surface subsystem includes acoustic transceiver and acoustic transducer units, which are configured to generate and omnidirectionally transmit an acoustic interrogation signal into the body of water surrounding the vessel and to directionally receive acoustic reply signals. The submerged subsystems include a compressed gas source and an enclosed flotation bag in fluid communication and an underwater acoustic actuator-transponder unit configured to receive the acoustic interrogation signal transmitted by the surface subsystem and to transmit an acoustic reply signal into the body of water. In addition, the submerged subsystem is further configured to control the flow of gas between the compressed gas source and the enclosed floatation bag to facilitate recovery of the submerged subsystem.

Abstract: The present disclosure relates to bilayer tablets comprising a second layer comprising a ?-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.

Abstract: An architecture for an inertial confinement fusion system is disclosed. The system includes a fusion chamber for producing neutrons from a fusion reaction, and a laser system in which lasers are arranged about a vacuum chamber to provide energy to the fusion chamber to initiate the fusion reaction. The beam paths between the lasers and the fusion chamber are configured to prevent neutrons from the fusion chamber from reaching the laser system at a level that would preclude human access to the laser system.

Abstract: The present disclosure relates to combinations of valproic acid or a pharmaceutically acceptable salt thereof, a ?-lactam compound or a pharmaceutically acceptable salt thereof, and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the combinations.

Abstract: The present disclosure relates to bilayer tablets comprising a second layer comprising a ?-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.

Abstract: The present disclosure relates to bilayer tablets comprising a second layer comprising a ?-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.

Abstract: The present disclosure relates to combinations of a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof a ?-lactam compound or a pharmaceutically acceptable salt thereof and probenecid or a pharmaceutically acceptable salt thereof.

Abstract: An architecture for a fusion power plant is disclosed. The plant includes a fusion chamber for producing neutrons from a fusion reaction, and a laser system in which lasers are arranged about a vacuum chamber to provide energy to the fusion chamber to initiate the fusion reaction. The beam paths between the lasers and the fusion chamber are configured to prevent neutrons from the fusion chamber from reaching the laser system at a level that would preclude human access to the laser system.

Abstract: The invention is a flexible mat that can be placed on a floor or other large flat surface for the purpose of serving as a fully functional, oversized membrane computer keyboard with enlarged characters and keypad area. Each character depicted on the keyboard indicates a particular letter, numeral, function or symbol for input. Thereby, its user can enter information into a computer or electronic device through the keyboard by using alternative methods of input to traditional finger keystrokes. Rather, the user may utilize feet, knees, hands or other body parts and non-body parts instead of only fingers.